Shandong Wohua Pharmaceutical Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE000001QB8
CNY
7.36
-0.15 (-2.0%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Mar'26
Dec'25
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Net Sales
219.05
192.34
199.25
207.52
217.84
183.77
178.26
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
219.05
192.34
199.25
207.52
217.84
183.77
178.26
Raw Material Cost
48.27
47.67
47.84
52.69
60.81
51.67
52.15
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.01
0.01
0.01
0.02
0.02
0.01
0.00
Selling and Distribution Expenses
116.75
100.94
121.26
121.65
119.45
105.17
108.26
Other Expenses
0.80
0.89
0.67
0.98
1.00
1.09
0.84
Total Expenditure (Excl Depreciation)
173.03
157.56
175.78
184.14
190.29
167.76
168.82
Operating Profit (PBDIT) excl Other Income
46
34.8
23.5
23.4
27.5
16
9.399999999999999
Other Income
1.68
2.64
1.97
2.60
2.35
1.92
1.71
Operating Profit (PBDIT)
43.90
41.57
29.14
28.67
33.84
25.52
19.26
Interest
0.01
0.01
0.01
0.02
0.02
0.01
0.00
Exceptional Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Gross Profit (PBDT)
170.78
144.67
151.42
154.83
157.02
132.10
126.11
Depreciation
0.00
7.67
7.67
7.73
7.73
8.03
8.03
Profit Before Tax
43.89
33.90
21.46
20.93
26.10
17.48
11.22
Tax
5.44
4.07
3.67
1.87
3.98
3.86
0.70
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
36.65
31.72
19.32
21.82
22.86
13.49
11.83
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
36.65
31.72
19.32
21.82
22.86
13.49
11.83
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
1.80
-1.90
-1.53
-2.75
-0.75
0.13
-1.31
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
38.45
29.82
17.79
19.07
22.11
13.62
10.52
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
676.19
723.82
692.10
742.04
720.23
697.37
683.87
Earnings per share (EPS)
0.06
0.06
0.03
0.04
0.04
0.02
0.02
Diluted Earnings per share
0.06
0.06
0.03
0.04
0.04
0.02
0.02
Operating Profit Margin (Excl OI)
19.28%
16.26%
9.79%
8.84%
10.91%
8.47%
5.34%
Gross Profit Margin
20.04%
21.61%
14.62%
13.81%
15.53%
13.88%
10.8%
PAT Margin
16.73%
16.49%
9.7%
10.51%
10.49%
7.34%
6.64%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - QoQ
stock-summary

Net Sales

QoQ Growth in quarter ended Mar 2026 is 13.88% vs -3.51% in Dec 2025

stock-summary

Consolidate Net Profit

QoQ Growth in quarter ended Mar 2026 is 29.19% vs 67.42% in Dec 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Mar 2026 is 8.48% vs 43.01% in Dec 2025

stock-summary

Interest

No Interest in the last few periods

stock-summary

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

Compare Quarterly Results Of Shandong Wohua Pharmaceutical Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(CNY)
Change(%)
Net Sales
219.05
0
219.05
Other Operating Income
0.00
0.00
0.00
Total Operating income
219.05
0
219.05
Raw Material Cost
48.27
0
48.27
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
0.01
0
0.01
Selling and Distribution Expenses
116.75
0
116.75
Other Expenses
0.80
0.00
0.80
Total Expenditure (Excl Depreciation)
173.03
0
173.03
Operating Profit (PBDIT) excl Other Income
46.01
0.00
46.01
Other Income
1.68
0
1.68
Operating Profit (PBDIT)
43.90
0
43.90
Interest
0.01
0
0.01
Exceptional Items
0.00
0
0.00
Gross Profit (PBDT)
170.78
0
170.78
Depreciation
0.00
0
0.00
Profit Before Tax
43.89
0
43.89
Tax
5.44
0
5.44
Provisions and contingencies
0
0
0.00
Profit After Tax
36.65
0
36.65
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
36.65
0
36.65
Share in Profit of Associates
0
0
0.00
Minority Interest
1.80
0
1.80
Other related items
0.00
0.00
0.00
Consolidated Net Profit
38.45
0
38.45
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
676.19
0
676.19
Earnings per share (EPS)
0.06
0
0.06
Diluted Earnings per share
0.06
0
0.06
Operating Profit Margin (Excl OI)
19.28%
0%
0.00
19.28%
Gross Profit Margin
20.04%
0%
0.00
20.04%
PAT Margin
16.73%
0%
0.00
16.73%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 21.90 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 13.88% vs -3.51% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 0.55% vs 2.74% in Mar 2025

Quarterly - Consolidate Net Profit
Consolidate Net Profit 3.85 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 29.19% vs 67.42% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 74.21% vs 151.14% in Mar 2025

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 4.22 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 8.48% vs 43.01% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 33.97% vs 103.23% in Mar 2025

Quarterly - Interest
Markets Mojo
No Interest in the last few periods
Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 19.28%
in Mar 2026

Figures in %
stock-summary

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025